Contacter le RP
Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.
Babbler permet aux journalistes et communicants de collaborer plus simplement.
En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !
Leurs espaces presse sont sur Babbler :
Vous êtes à 1 clic de l'inscription !
Content de vous revoir !
Central Venous Catheter Market Is Booming Across the Globe Explored in Latest Research
minutes de lecture
minute de lecture
Central venous catheters consist of a long, thin tube that is inserted into a large vein to deliver medication, nutrition, intravenous fluids, and cancer medications. Different types of central venous catheters can be utilized by patients according to the duration of the treatment, which includes tunneled central venous catheters (CVC) and implanted ports for long term use, peripherally inserted central catheter (PICC) for intermediate term and nontunneled CVC for short term use.
Increasing prevalence of renal diseases is a major factor driving central venous catheter market growth. According to the research survey done by U.S. Renal Data System (USRDS), in 2017, around 440,000 patients are living with End-Stage Renal Disease (ESRD) in the U.S and require hemodialysis for survival annually. Moreover, introduction of innovative products and increasing requirement of long-duration IV therapies such as chemotherapy is expected to boost the market growth. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. Food and Drug Administration (FDA) clearance for a broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2400
Increasing prevalence of cancer and renal diseases is expected to propel growth of central venous catheter market
Central venous catheterization is used for chemotherapy administration, total parenteral nutrition, administration of intravenous fluids, administration of blood and platelet transfusions, and other uses. High prevalence of cancer is expected to propel demand for central venous catheterization, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.
Similarly, according to the study by University of California, 2014, around 2 million people worldwide are affected by end stage renal disease (ESRD) and the number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually.
Increasing adoption of central venous catheters in North America is expected to bolster the market growth
North America holds dominant position in the global central venous catheter market, owing to high availability of catheters in medical settings. According to the survey by PavMed, 2016, around 7 million central vascular access devices are utilized annually in the U.S., which includes 400-500,000 implantable ports. Increasing prevalence of cancer in the region is also expected to boost the market growth. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.
Major players operating in the global central venous catheter market include, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation.
To Avail Discount on This Report @ https://www.coherentmarketinsights.com/insight/request-discount/2400
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at firstname.lastname@example.org
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
- Health & Medicine
Félicitations, vous êtes inscrit sur BABBLER !
Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !
Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici
- Health & Medicine